Gemini Therapeutics Inc. (GMTX) Fundamentals

Gemini Therapeutics Inc is a clinical-stage precision medicine company developing novel therapeutic compounds to treat genetically defined AMD. Its candidate, GEM103, is a recombinant form of the Complement Factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health.
SHARE INFORMATION
Market Cap$ 83,428,417
Shares Outstanding43,227,159
Float22,440,214
Percent Float51.91%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 0
Latest Fiscal EPS$ -1.81
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions136
Institutional Holdings Date2022-07-31
Institutional Bought Previous 3 Months1,070,818
Institutional Holdings Percent57.8%
Institutional Sold Previous 3 Months6,300,315
Insider Holdings Date2022-07-31
Insider Bought Previous 3 Months9,960
Insider Holdings Percent0.9
Insider Sold Previous 3 Months-
Insider Shares Owned405,237
TRADING INFO
52 Week High$ 5.48
52 Week Low$ 1.16
52 Week High Change$ -52.46
21 Day Moving Average$ 1.6119
21 Day Extended Moving Average$ 1.6426
50 Day Moving Average$ 1.5764
50 Day Extended Moving Average$ 1.5932
200 Day Moving Average$ 1.9646
200 Day Extended Moving Average$ 2.5352
10 Day Average Volume242,325
20 Day Average Volume160,276
30 Day Average Volume156,715
50 Day Average Volume190,989
Alpha-0.099379
Beta-0.4768
Standard Deviation0.211818
R20.013597
7 Day Price Change$ 0.35
7 Day Percent Change22.15%
21 Day Price Change$ 0.35
21 Day Percent Change22.15%
30 Day Price Change$ 0.27
30 Day Percent Change16.27%
Month to Date Price Change$ 0.40
Month to Date Percent Change26.14%
Quarter to Date Price Change$ 0.24
Quarter to Date Percent Change14.2%
180 Day Price Change$ 0.29
180 Day Percent Change17.68%
200 Day Price Change$ 0.06
200 Day Percent Change3.21%
Year to Date Price Change$ -0.98
Year to Date Percent Change-33.68%

Gemini Therapeutics Inc. (GMTX) Key Ratios

PROFITABILITY
EBIT Margin0.0%
EBITDA Margin0.0%
Pre-Tax Profit Margin0.0%
Profit Margin Count0.0%
Gross Margin0.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 0
Revenue Per Share$ 0.00
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book0.80
Total Debt To Equity0.00
Int Coverage-180.00
Current Ratio9.80
Leverage Ratio1.10
Quick Ratio9.40
Long Term Debt To Capital0.00
VALUATION MEASURES
PE Ratio-1.30
Enterprise Value$ -28,018,411
Price to Sales0.00
Price to Free Cash-1.90
PE High Last 5 Years0.00
Price To Book0.80
Price To Cash Flow0.00
PE Low Last 5 Years0.00
Price to Tangible Book0.80
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.00
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-43.39
Return on Equity-48.13
Return on Capital-46.38

Gemini Therapeutics Inc. (GMTX) Profile

PROFILE INFO
Issue TypeCS
SEC Type-
AuditorErnst & Young LLP
CEOGeorges Gemayel
Emplyoees33
Last AuditUQ
CIK0001816736
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address300 One Kendall Square
3rd Floor
Cambridge, MA 2139
Websitehttps://www.geminitherapeutics.com
Facsimile-
Telephone+1 617 401-4400
Email-


Your Recent History
NASDAQ
GMTX
Gemini The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.